Johnson & Johnson said worldwide sales for Q1 2025 were $21.9 billion, a total increase of 2.4%, which included operational growth of 4.2% and a negative currency impact of 1.8%. The company said the impact of the Stelara sales decline on worldwide operational sales was approximately negative 4.7%.

1. 01

   Johnson & Johnson said worldwide sales for Q1 2025 were $21.9 billion, a total increase of 2.4%, which included operational growth of 4.2% and a negative currency impact of 1.8%. The company said the impact of the Stelara sales decline on worldwide operational sales was approximately negative 4.7%.

2. 02

   Johnson & Johnson said consolidated earnings before provision for taxes on income for Q1 2025 were $13.6 billion, representing 62.3% of sales, compared to $3.7 billion (17.4% of sales) for Q1 2024. Q1 2025 included the reversal of approximately $7.0 billion of the previously accrued talc reserve.

3. 03

   Johnson & Johnson said Innovative Medicine segment sales for Q1 2025 were $13.9 billion, an increase of 2.3%, and MedTech segment sales were $8.0 billion, an increase of 2.5%. Operational growth rates were 4.2% and 4.1%, respectively.

4. 04

   Johnson & Johnson said as of March 30, 2025, cash, cash equivalents and marketable securities were approximately $38.8 billion, notes payable and long-term debt were approximately $52.3 billion, for a net debt position of $13.5 billion. The company said it issued senior unsecured notes for approximately $9.2 billion in Q1, and the net proceeds were used to fund the Intra-Cellular Therapies acquisition for approximately $14.6 billion, which closed on April 2, 2025, and for general corporate purposes.

Key figures

Quarter ended March 30, 2025

Revenue

$21.9B

Net income

$11.0B

EPS

$4.54

Gross profit

$14.5B

Operating cash flow

$4.2B

Analysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.